Overexpression of acid sphingomyelinase (ASM) in the forebrain affects addiction-related behaviors differently in male and female mice. In males, forebrain ASM overexpression increased alcohol consumption in a free-choice paradigm and reduced conditioned place preference (CPP) for alcohol and cocaine, but not for amphetamine, ketamine, or high-fat/carbohydrate food. In females, it increased binge-like alcohol drinking while moderate consumption remained unchanged, and enhanced CPP for amphetamine but not other substances. These findings suggest ASM plays a sex-specific role in the reinforcing effects of certain addictive substances, offering potential molecular targets for drug- and sex-specific therapies.
Cannabinoids, despite their illegal status, have recognized therapeutic potential and are often used recreationally by young adults, sometimes as an alternative to other drugs or to enhance pleasure. They are frequently taken alongside medications for alcohol use disorder (AUD) and alcohol withdrawal syndrome (AWS), such as disulfiram, acamprosate, and naltrexone. This paper reviews recent findings on possible beneficial effects and interactions between cannabinoids and these AUD/AWS medications, whether the conditions are comorbid or separate.